Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial.-Reference-Cited by-同舟云学术

Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial.

Published:2014-05-20 Issue:15_suppl Volume:32 Page:3600-3600
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Heinemann Volker¹,Modest Dominik Paul¹,Fischer von Weikersthal Ludwig²,Decker Thomas³,Kiani Alexander⁴,Vehling-Kaiser Ursula⁵,Al-Batran Salah-Eddin⁶,Heintges Tobias⁷,Lerchenmuller Christian A.⁸,Kahl Christoph⁹,Seipelt Gernot¹⁰,Kullmann Frank¹¹,Stauch Martina¹²,Scheithauer Werner¹³,Held Swantje¹⁴,Giessen Clemens Albrecht¹⁵,Jung Andreas¹⁶,Kirchner Thomas¹⁶,Stintzing Sebastian¹⁷

Affiliation:

1. Department of Medical Oncology, Klinikum Grosshadern, University of Munich, Munich, Germany

2. Health Center St. Marien GmbH, Amberg, Germany

3. Onkologie Ravensburg, Ravensburg, Germany

4. Klinikum Bayreuth, Bayreuth, Germany

5. Practice for Medical Oncology, Landshut, Germany

6. Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt am Main, Germany

7. Städtisches Klinikum Neuss Lukaskrankenhaus GmbH, Medical Department II, Neuss, Germany

8. Private Practice for Oncology, Muenster, Germany

9. Department for Hematology, Klinikum Magdeburg, Magdeburg, Germany

10. Onkologische Schwerpunktpraxis, Bad Soden, Germany

11. Klinikum Weiden, Weiden, Germany

12. Onkologische Schwerpunktpraxis Kronach, Kronach, Germany

13. Medical University of Vienna, Vienna, Austria

14. ClinAssess GmbH, Leverkusen, Germany

15. Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany

16. Department of Pathology, University of Munich, Munich, Germany

17. Department of Hematology and Oncology, Klinikum Grosshadern and Comprehensive Cancer Center, LMU Munich, Munich, Germany

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2014.32.15_suppl.3600

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A multicenter, prospective, phase II trial of second‐line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to an anti‐EGFR antibody: HGCSG1801;International Journal of Cancer;2024-08-14

2. Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies;Frontiers in Oncology;2022-11-09

3. Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone;British Journal of Cancer;2021-07-12

4. The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study;Journal of Gastrointestinal Cancer;2020-09-11

5. Epidermal growth factor receptor ligands: targets for optimizing treatment of metastatic colorectal cancer;Growth Factors;2019-11-02